Actively Recruiting
Registry of Patients Having Received oNKord®
Led by Glycostem Therapeutics BV · Updated on 2022-08-04
50
Participants Needed
2
Research Sites
298 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
ReKORD is an observational study (Registry) enrolling participants who have received at least one dose of oNKord® (allogeneic ex vivo-generated Natural Killer \[NK\] cells from CD34+ umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple previous clinical trials of oNKord® can be enrolled in this Registry.
CONDITIONS
Official Title
Registry of Patients Having Received oNKord®
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Receipt of at least one dose of oNKord4 in a clinical trial
- Participation must be within 3 years after the first infusion of oNKord4
- Signature of informed consent form
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Medizinische Hochschule Hannover
Hanover, Germany
Actively Recruiting
2
University Hospital Basel
Basel, Switzerland
Actively Recruiting
Research Team
K
Katarzyna Nowek, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here